NCT00093873CompletedPhase 1
A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Amgen
- Enrollment
- 71
- Primary Endpoint
- Dose limiting toxicity
Study Overview
Brief Summary
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
AMG 706
Experimental
AMG 706 QD
Intervention: Anti-angiogenesis (Drug)
AMG 706
Experimental
AMG 706 QD
Intervention: AMG 706 (Drug)
Outcomes
Primary Outcomes
Dose limiting toxicity
Time Frame: Cycle 1
Secondary Outcomes
- Dose selection(Study completion)
Investigators
Similar Trials
Terminated
Phase 1
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT01137552Amgen44
Completed
Phase 1
M1231 in Participants With Solid TumorsMetastatic Solid TumorsEsophageal CancerNon-Small Cell Lung CancerNCT04695847EMD Serono Research & Development Institute, Inc.23
Completed
Phase 1
Study of AMG 650 in Adult Participants With Advanced Solid TumorsAdvanced Solid TumorsNCT04293094Volastra Therapeutics, Inc.66
Completed
Phase 1
A Study of AMG 337 in Subjects With Advanced Solid TumorsAdvanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumorsNCT01253707Amgen111
Completed
Phase 1
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLCCarcinoma, Non-Small-Cell LungAdenocarcinomaBreast CancerColorectal CancerPancreatic CancerNCT01761240Morphotek27